Who Generates More Revenue? argenx SE or Xencor, Inc.

Revenue Race: Argenx SE vs. Xencor, Inc.

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Argenx SE and Xencor, Inc. have been vying for dominance. From 2014 to 2023, Argenx SE has shown a remarkable growth trajectory, culminating in a staggering 1,226% increase in revenue by 2023. In contrast, Xencor, Inc. has experienced a more modest growth, with a 177% increase over the same period.

A Decade of Growth

Argenx SE's revenue surged significantly in 2023, reaching a peak that was nearly three times its 2022 figures. This growth can be attributed to strategic advancements in their therapeutic offerings. Meanwhile, Xencor, Inc. maintained steady growth, with its highest revenue recorded in 2021. The data highlights the dynamic nature of the biotech industry, where innovation and strategic planning are crucial for financial success.